DE69226197D1 - Hämoglobine als arzneimittelabgabesystem - Google Patents
Hämoglobine als arzneimittelabgabesystemInfo
- Publication number
- DE69226197D1 DE69226197D1 DE69226197T DE69226197T DE69226197D1 DE 69226197 D1 DE69226197 D1 DE 69226197D1 DE 69226197 T DE69226197 T DE 69226197T DE 69226197 T DE69226197 T DE 69226197T DE 69226197 D1 DE69226197 D1 DE 69226197D1
- Authority
- DE
- Germany
- Prior art keywords
- hemoglobine
- delivery system
- medicine delivery
- hemoglobin
- tracer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6445—Haemoglobin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78917791A | 1991-11-08 | 1991-11-08 | |
| US07/789,179 US5545727A (en) | 1989-05-10 | 1991-11-08 | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
| PCT/US1992/009713 WO1993008842A1 (en) | 1991-11-08 | 1992-11-06 | Hemoglobins as drug delivery agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69226197D1 true DE69226197D1 (de) | 1998-08-13 |
| DE69226197T2 DE69226197T2 (de) | 1999-02-11 |
Family
ID=27120889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69226197T Expired - Lifetime DE69226197T2 (de) | 1991-11-08 | 1992-11-06 | Hämoglobine als arzneimittelabgabesystem |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US5679777A (de) |
| EP (1) | EP0611306B1 (de) |
| JP (1) | JP3426599B2 (de) |
| AT (1) | ATE168014T1 (de) |
| AU (1) | AU665599B2 (de) |
| CA (1) | CA2122717C (de) |
| DE (1) | DE69226197T2 (de) |
| WO (1) | WO1993008842A1 (de) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478806A (en) * | 1989-11-22 | 1995-12-26 | Enzon, Inc. | Enhancement of antitumor therapy with hemoglobin-based conjugates |
| AU665599B2 (en) * | 1991-11-08 | 1996-01-11 | Hemosol Inc. | Hemoglobins as drug delivery agents |
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| WO1994022482A1 (en) * | 1993-03-26 | 1994-10-13 | Biorelease Technologies, Inc. | Compositions including heme-containing proteins and methods relating thereto |
| US5665869A (en) * | 1993-11-15 | 1997-09-09 | Somatogen, Inc. | Method for the rapid removal of protoporphyrin from protoporphyrin IX-containing solutions of hemoglobin |
| US6458762B1 (en) | 1994-03-28 | 2002-10-01 | Baxter International, Inc. | Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis |
| US5670347A (en) | 1994-05-11 | 1997-09-23 | Amba Biosciences Llc | Peptide-mediated gene transfer |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP1950298A3 (de) | 1997-05-02 | 2008-12-24 | Baxter Biotech Technology S.A.R.L. | Hämoglobinmutanten mit erhöhtem Löslichkeitswert und/oder reduzierter Stickoxidspülung |
| PT1001978E (pt) * | 1997-06-24 | 2005-08-31 | Proteus Molecular Design | Derivados da angiotensina |
| US7378489B1 (en) | 1999-12-23 | 2008-05-27 | Protherics Medicines Development Limited | Angiotensin derivatives |
| CA2236344A1 (en) * | 1998-04-30 | 1999-10-30 | Hemosol Inc. | Hemoglobin-haptoglobin complexes |
| US20050059576A1 (en) * | 1998-04-30 | 2005-03-17 | Adamson J. Gordon | Targeted delivery of antiviral compounds through hemoglobin bioconjugates |
| US7816403B2 (en) * | 1998-09-08 | 2010-10-19 | University Of Utah Research Foundation | Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same |
| US6548540B2 (en) * | 1998-09-08 | 2003-04-15 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
| US6706759B1 (en) | 1998-09-08 | 2004-03-16 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using dithiocarbamate derivatives |
| US6589987B2 (en) | 1998-09-08 | 2003-07-08 | Charlotte-Mecklenburg Hospital Authority | Method of treating cancer using tetraethyl thiuram disulfide |
| US6706252B1 (en) | 1998-10-30 | 2004-03-16 | Rx/Ibr Corporation | Method of treating disease with radioisotopes conjugated to bioactive substances |
| DE19926475A1 (de) * | 1999-06-10 | 2000-12-14 | Ktb Tumorforschungs Gmbh | Träger-Pharmaka-Konjugate |
| ATE337403T1 (de) * | 1999-12-24 | 2006-09-15 | Genentech Inc | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
| US20060228364A1 (en) * | 1999-12-24 | 2006-10-12 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US20040001827A1 (en) * | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
| US6749865B2 (en) | 2000-02-15 | 2004-06-15 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
| AU2001238346A1 (en) | 2000-02-15 | 2001-08-27 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
| US6946134B1 (en) | 2000-04-12 | 2005-09-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP1276849A4 (de) * | 2000-04-12 | 2004-06-09 | Human Genome Sciences Inc | Albumin fusionsproteine |
| US20050244931A1 (en) * | 2001-04-12 | 2005-11-03 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20060084794A1 (en) * | 2001-04-12 | 2006-04-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7507413B2 (en) | 2001-04-12 | 2009-03-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20050054051A1 (en) * | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003030821A2 (en) * | 2001-10-05 | 2003-04-17 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
| US7214660B2 (en) | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
| GB0125793D0 (en) * | 2001-10-26 | 2001-12-19 | Panzeri Ezio | Method |
| EP2277889B1 (de) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Fusionsproteine von Albumin und Interferon beta |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US20070026485A1 (en) | 2003-04-09 | 2007-02-01 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| US7235639B2 (en) | 2003-04-23 | 2007-06-26 | Ezio Panzeri | Hemoglobin conjugates |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| WO2006041641A2 (en) * | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Therapeutic agents with decreased toxicity |
| ES2572779T3 (es) | 2004-10-29 | 2016-06-02 | Ratiopharm Gmbh | Remodelación y glucopegilación del Factor de Crecimiento de Fibroblastos (FGF) |
| ES2449195T3 (es) | 2005-01-10 | 2014-03-18 | Ratiopharm Gmbh | Factor estimulante de colonias de granulocitos glicopegilado |
| EP2386571B1 (de) | 2005-04-08 | 2016-06-01 | ratiopharm GmbH | Zusammensetzungen und Verfahren zur Herstellung von Glycosylierungsmutanten eines Proteaseresistenten menschlichen Wachstumshormons |
| JP5335422B2 (ja) | 2005-06-17 | 2013-11-06 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 少なくとも１つの非天然のシステインを含んでいる操作されたタンパク質の選択的な還元および誘導体化 |
| US7507842B2 (en) | 2005-08-12 | 2009-03-24 | Radiorx, Inc. | Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| DE102006011660A1 (de) * | 2006-03-12 | 2007-09-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur Ermittlung einer Dotierungsdichte in einer Halbleiterprobe |
| US9187532B2 (en) | 2006-07-21 | 2015-11-17 | Novo Nordisk A/S | Glycosylation of peptides via O-linked glycosylation sequences |
| EP2054521A4 (de) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Verfahren zur reinigung von polypeptid-konjugate |
| US7504377B2 (en) * | 2006-10-23 | 2009-03-17 | Ikor, Inc. | Nitric oxide-blocked cross-linked tetrameric hemoglobin |
| AU2007331195A1 (en) | 2006-12-12 | 2008-06-19 | Biorexis Pharmaceutical Corporation | Transferrin fusion protein libraries |
| CA2682897C (en) | 2007-04-03 | 2016-11-22 | Biogenerix Ag | Methods of treatment using glycopegylated g-csf |
| CN101778859B (zh) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | 改良的用于生产核苷酸糖的方法 |
| BRPI0721948A2 (pt) * | 2007-08-20 | 2014-04-08 | Enzon Pharmaceuticals Inc | Ligantes poliméricos contendo frações dissulfeto de piridila |
| US20130189239A1 (en) | 2008-02-27 | 2013-07-25 | Novo Nordisk A/S | Conjugated Factor VIII Molecules |
| US8436140B2 (en) * | 2008-06-02 | 2013-05-07 | Washington University | Natriuretic peptide-mediated imaging of atherosclerotic plaque |
| US20140308260A1 (en) | 2011-10-07 | 2014-10-16 | Radiorx, Inc. | Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products |
| ES2935573T3 (es) | 2011-10-07 | 2023-03-08 | Epicentrx Inc | Compuestos de organonitro tioéter y usos médicos de estos |
| US10883119B2 (en) * | 2012-07-11 | 2021-01-05 | Sangamo Therapeutics, Inc. | Methods and compositions for delivery of biologics |
| US9636404B2 (en) * | 2013-05-13 | 2017-05-02 | Vision Global Holdings Ltd. | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
| US9814759B2 (en) * | 2014-07-02 | 2017-11-14 | Cheer Global Ltd. | Pharmaceutical composition comprising recombinant hemoglobin protein or subunit-based therapeutic agent for cancer targeting treatment |
| PL412787A1 (pl) | 2015-06-22 | 2017-01-02 | Magdalena Król | Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną |
| US10342778B1 (en) | 2015-10-20 | 2019-07-09 | Epicentrx, Inc. | Treatment of brain metastases using organonitro compound combination therapy |
| US9987270B1 (en) | 2015-10-29 | 2018-06-05 | Epicentrix, Inc. | Treatment of gliomas using organonitro compound combination therapy |
| JP6931004B2 (ja) | 2016-01-11 | 2021-09-01 | エピセントアールエックス，インコーポレイテッド | ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法 |
| WO2017197499A1 (en) * | 2016-04-25 | 2017-11-23 | The Governing Council Of The University Of Toronto | Stabilized hemoglobin-avidin assembly and method of preparation |
| WO2017221185A1 (en) * | 2016-06-21 | 2017-12-28 | Therapure Biopharma Inc. | Hemoglobin-targeted drug delivery for the treatment of cancer |
| WO2018071741A1 (en) | 2016-10-14 | 2018-04-19 | Epicentrix, Inc. | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |
| JP2020506974A (ja) * | 2017-02-08 | 2020-03-05 | エイチケイエル・メディカル・エルエルシー | 部位内投与およびそれに使用するための投薬方法および医薬 |
| MX2020000265A (es) | 2017-07-07 | 2020-07-22 | Epicentrx Inc | Composiciones para la administración parenteral de agentes terapéuticos. |
| WO2019164593A2 (en) | 2018-01-08 | 2019-08-29 | Epicentrx, Inc. | Methods and compositions utilizing rrx-001 combination therapy for radioprotection |
| EP3650046A1 (de) | 2018-11-08 | 2020-05-13 | Cellis AG | System auf basis mesenchymaler stammzellen zur gezielten wirkstoffabgabe |
| WO2024056413A1 (en) | 2022-09-13 | 2024-03-21 | Cellis Ag | Isolated targeted delivery system for the treatment of glioma |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3934008A (en) * | 1968-08-23 | 1976-01-20 | Ciba-Geigy Corporation | N-acyl and desamino human calcitonin and analogs thereof |
| US3980764A (en) * | 1973-11-05 | 1976-09-14 | Curtis Nuclear Corporation | Polymeric competitive protein binding adsorbents for radioassey |
| US4042677A (en) * | 1974-08-29 | 1977-08-16 | Union Carbide Corporation | Technetium-99m labeled radiodiagnostic agents and method of preparation |
| DE2449885C3 (de) * | 1974-10-21 | 1980-04-30 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat |
| US4061736A (en) * | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
| US4001401A (en) * | 1975-02-02 | 1977-01-04 | Alza Corporation | Blood substitute and blood plasma expander comprising polyhemoglobin |
| US4001200A (en) * | 1975-02-27 | 1977-01-04 | Alza Corporation | Novel polymerized, cross-linked, stromal-free hemoglobin |
| US4053590A (en) * | 1975-02-27 | 1977-10-11 | Alza Corporation | Compositions of matter comprising macromolecular hemoglobin |
| DE2740053A1 (de) * | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
| DE2843963A1 (de) * | 1978-10-09 | 1980-04-24 | Merck Patent Gmbh | Im koerper resorbierbare geformte masse auf basis von kollagen und ihre verwendung in der medizin |
| JPS6023084B2 (ja) * | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4769326A (en) * | 1980-02-29 | 1988-09-06 | The Regents Of The University Of California | Expression linkers |
| US4338397A (en) * | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| DE3171463D1 (en) * | 1980-04-28 | 1985-08-29 | Nat Res Dev | Improvements in or relating to porous glass |
| JPS5716815A (en) * | 1980-07-02 | 1982-01-28 | Ajinomoto Co Inc | Oxygen transporting agent for artificial blood |
| US4551433A (en) * | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
| US4374932A (en) * | 1981-06-08 | 1983-02-22 | G. D. Searle & Co. | 5-ASA Drug delivery system |
| JPS57206622A (en) * | 1981-06-10 | 1982-12-18 | Ajinomoto Co Inc | Blood substitute |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4500507A (en) * | 1981-10-30 | 1985-02-19 | Wong Dennis W | Diagnostic composition for radiologic imaging of neoplasms in the body and method of preparation |
| DE3144705C2 (de) * | 1981-11-11 | 1983-12-08 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Herstellung eines lagerstabilen, vernetzten Hämoglobinpräparates mit hoher Sauerstoff-Transportkapazität, sowie das nach diesem Verfahren hergestellte Hämoglobinpräparat |
| US4540564A (en) * | 1982-05-18 | 1985-09-10 | University Of Florida | Brain-specific drug delivery |
| IT1153000B (it) * | 1982-07-01 | 1987-01-14 | Resem Spa | Dispersioni acquose di poliuretani da oligouretani aventi gruppi terminali insaturi |
| US4599197A (en) * | 1982-12-22 | 1986-07-08 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4512922A (en) * | 1982-12-22 | 1985-04-23 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4620948A (en) * | 1982-12-22 | 1986-11-04 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4511503A (en) * | 1982-12-22 | 1985-04-16 | Genentech, Inc. | Purification and activity assurance of precipitated heterologous proteins |
| US4713339A (en) * | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4529719A (en) * | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| GB8328917D0 (en) * | 1983-10-28 | 1983-11-30 | Fisons Plc | Blood substitute |
| US4840896A (en) * | 1983-11-02 | 1989-06-20 | Integrated Genetics, Inc. | Heteropolymeric protein |
| US4738952A (en) * | 1984-04-27 | 1988-04-19 | Synthetic Blood Corporation | Substitute for human blood and a method of making the same |
| GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
| US4598064A (en) * | 1984-06-27 | 1986-07-01 | University Of Iowa Research Foundation | Alpha-alpha cross-linked hemoglobins |
| US4600531A (en) * | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US4625014A (en) * | 1984-07-10 | 1986-11-25 | Dana-Farber Cancer Institute, Inc. | Cell-delivery agent |
| US4542225A (en) * | 1984-08-29 | 1985-09-17 | Dana-Farber Cancer Institute, Inc. | Acid-cleavable compound |
| JPS6191131A (ja) * | 1984-10-09 | 1986-05-09 | Chugai Pharmaceut Co Ltd | 医薬品の吸着防止方法および組成物 |
| US4774180A (en) * | 1986-02-26 | 1988-09-27 | Massachusetts Institute Of Technology | Construction and application of polyproteins |
| EP0210204B1 (de) * | 1985-01-18 | 1988-12-07 | Kailash Kumar Dr. Prof. Gauri | Proteinhydrolysate, verfahren zu ihrer herstellung und arzneimittel, die diese hydrolysate enthalten |
| US4584130A (en) * | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| DE3515252C2 (de) * | 1985-04-27 | 1994-02-24 | Roehm Gmbh | Verfahren zur Immobilisierung gelöster Eiweißstoffe |
| SE456136B (sv) * | 1985-06-17 | 1988-09-12 | Oncholab Ab | Forfarande for framstellning av en med ett lipofilt biologiskt aktivt emne bemengd berare pa basis av rekonstituerat ldl (lagdensitetslipoprotein) |
| DE3675588D1 (de) * | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| EP0238645A1 (de) * | 1985-10-03 | 1987-09-30 | Biotechnology Research Partners, Ltd. | Neue arzneimittel verabreichende systeme auf der basis von lipoproteinen |
| US4783529A (en) * | 1985-12-03 | 1988-11-08 | Research Corporation Technologies | Rapid synthesis of radiolabeled porphyrin complexes for medical application |
| US4849142A (en) * | 1986-01-03 | 1989-07-18 | Jupiter Technologies, Inc. | Superplastic forging of zirconia ceramics |
| US4826811A (en) * | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4730936A (en) * | 1986-10-10 | 1988-03-15 | The United States Of America As Represented By The Secretary Of The Air Force | Gas driven system for preparing large volumes of non-oxidized, pyridoxylated, polymerized stroma-free hemoglobin solution for use as a blood substitute |
| DE3636590A1 (de) * | 1986-10-28 | 1988-05-26 | Braun Melsungen Ag | Blutersatzmittel |
| DE3702105A1 (de) * | 1987-01-24 | 1988-08-04 | Bayer Ag | Parenterale loesung |
| WO1988006601A1 (en) * | 1987-03-02 | 1988-09-07 | Genex Corporation | Gene repressors |
| GB8711614D0 (en) | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
| US5069936A (en) * | 1987-06-25 | 1991-12-03 | Yen Richard C K | Manufacturing protein microspheres |
| US5049493A (en) * | 1987-10-23 | 1991-09-17 | California Institute Of Technology | Enhancement of cell growth by expression of a cloned hemoglobin gene |
| EP0319206A3 (de) * | 1987-11-30 | 1990-04-18 | Berlex Laboratories, Inc. | Gen-Vermehrung |
| JP2561122B2 (ja) * | 1988-04-13 | 1996-12-04 | 寳酒造株式会社 | 機能性ポリペプチド |
| AU632474B2 (en) * | 1988-04-14 | 1993-01-07 | Incyte Pharmaceuticals, Inc. | 14-beta-gal mammalian lectins |
| US5137819A (en) * | 1988-07-08 | 1992-08-11 | University Of British Columbia | Cellulose binding fusion proteins for immobilization and purification of polypeptides |
| IL87708A (en) * | 1988-09-08 | 1994-04-12 | Technion Inst For Research And | Hemoglobin-based blood substitute possessing a colloid oncotic pressure substantially similar to human blood and method for the preparation thereof |
| IE63847B1 (en) * | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| NL8901174A (nl) * | 1989-05-10 | 1990-12-03 | Het Hoofd Van De Afdeling Mili | Hemoglobine-preparaat en gebruik daarvan. |
| US5545727A (en) * | 1989-05-10 | 1996-08-13 | Somatogen, Inc. | DNA encoding fused di-alpha globins and production of pseudotetrameric hemoglobin |
| ES2093640T3 (es) * | 1989-05-10 | 1997-01-01 | Somatogen Inc | Produccion de hemoglobina y sus analogos mediante bacterias y levadura. |
| US5599907A (en) * | 1989-05-10 | 1997-02-04 | Somatogen, Inc. | Production and use of multimeric hemoglobins |
| FR2650598B1 (fr) * | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5173426A (en) * | 1989-10-06 | 1992-12-22 | Yale University | DNAs encoding genetically engineered low oxygen affinity mutants of human hemoglobin |
| JP2829397B2 (ja) * | 1989-10-09 | 1998-11-25 | 寳酒造株式会社 | フィブリン結合活性ポリペプチド |
| US5234903A (en) * | 1989-11-22 | 1993-08-10 | Enzon, Inc. | Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute |
| DE3938953A1 (de) * | 1989-11-24 | 1991-05-29 | Max Planck Gesellschaft | Klonierung und expression des fuer die blut-hirn-schranke spezifischen proteins ht7 |
| DK608589D0 (da) * | 1989-12-01 | 1989-12-01 | Holm Arne | Kemisk fremgangsmaade |
| EP0505566A1 (de) * | 1989-12-15 | 1992-09-30 | Takeda Chemical Industries, Ltd. | Biospezifische antikörper gegen krebszellen und enzyme mit wirkstoffvorläufer-aktivierenden eigenschaften |
| US5250665A (en) * | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
| AU665599B2 (en) * | 1991-11-08 | 1996-01-11 | Hemosol Inc. | Hemoglobins as drug delivery agents |
-
1992
- 1992-11-06 AU AU31324/93A patent/AU665599B2/en not_active Ceased
- 1992-11-06 US US08/240,711 patent/US5679777A/en not_active Expired - Lifetime
- 1992-11-06 JP JP50878193A patent/JP3426599B2/ja not_active Expired - Lifetime
- 1992-11-06 CA CA002122717A patent/CA2122717C/en not_active Expired - Lifetime
- 1992-11-06 AT AT92925154T patent/ATE168014T1/de not_active IP Right Cessation
- 1992-11-06 WO PCT/US1992/009713 patent/WO1993008842A1/en active IP Right Grant
- 1992-11-06 EP EP92925154A patent/EP0611306B1/de not_active Expired - Lifetime
- 1992-11-06 DE DE69226197T patent/DE69226197T2/de not_active Expired - Lifetime
-
1995
- 1995-06-01 US US08/457,753 patent/US5759517A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2122717A1 (en) | 1993-05-13 |
| US5679777A (en) | 1997-10-21 |
| US5759517A (en) | 1998-06-02 |
| JPH07500840A (ja) | 1995-01-26 |
| EP0611306A1 (de) | 1994-08-24 |
| ATE168014T1 (de) | 1998-07-15 |
| JP3426599B2 (ja) | 2003-07-14 |
| DE69226197T2 (de) | 1999-02-11 |
| CA2122717C (en) | 2003-07-15 |
| AU3132493A (en) | 1993-06-07 |
| AU665599B2 (en) | 1996-01-11 |
| WO1993008842A1 (en) | 1993-05-13 |
| EP0611306B1 (de) | 1998-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69226197T2 (de) | Hämoglobine als arzneimittelabgabesystem | |
| MY105482A (en) | Boronic acid adducts of rhenium dioxime and technetium-99m dioxime complexes containing a biochemically active group. | |
| IL93983A0 (en) | Method for enhanced transmembrane transport of exogenous molecules | |
| EA199800946A1 (ru) | Концентрированный препарат антител | |
| MX9605940A (es) | Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones. | |
| DE69200490D1 (de) | Tischgestell für medizinische Untersuchung. | |
| FR2649613B1 (fr) | Medicament vaso-actif | |
| ATA84882A (de) | Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut | |
| DK642587A (da) | Insulinpraeparat | |
| GR3026658T3 (en) | Hydrazino-type radionuclide chelators having an n 3?s configuration | |
| DK0600930T3 (da) | Diagnose og behandling af autoimmune sygdomme | |
| SV1998000122A (es) | Medicamentos ref. pu 3375/sv | |
| DE68906153T2 (de) | Humanes relaxinpräparat. | |
| WO1992019213A3 (en) | Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy | |
| FI950062A0 (fi) | Proteiinien foroaktivaatio konjugaatiotarkoituksia varten | |
| NO981071D0 (no) | Hydrolyse-fremmende taksan-hydrofobiske derivater | |
| DE68909409T2 (de) | Heilmitteldosierung zur verabreichung an fische. | |
| DE3882157D1 (de) | Nichtsteroide antientzuendungswirkstoffe enthaltende pharmazeutische zubereitungen. | |
| SE8602743L (sv) | Bruksferdiga injektionslosningar innehallande en antitumorantracyklinglykosid | |
| SE9402880D0 (sv) | New peptide derivatives | |
| SE8404283L (sv) | Anvendning av ett specifikt tumorassocierat antigen, nemligen sialosyllaktotetraos, for diagnostiska och terapeutiska forfaranden vid cancersjukdomar | |
| ES2107431T3 (es) | Agentes con accion selectiva sobre los receptores de la adenosina. | |
| IT1226072B (it) | Soluzioni iniettabili pronte all'uso contenenti un glicoside antraciclinico antitumorale. | |
| ES2038064B1 (es) | Instalacion portatil de vacunacion aviar. | |
| DK0649433T3 (da) | Antigeniske regioner fra komplekser af tumorfrigivne partikler (TLP) og antistoffer mod sådanne. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: BAXTER BIOTECH TECHNOLOGY S.A.R.L., NEUCHATEL, CH |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: HEMOSOL INC., ETOBICOKE, ONTARIO, CA |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: THERAPURE BIOPHARMA INC., MISSISSAUGA, ONTARIO, CA |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: REHBERG HUEPPE + PARTNER, 37073 GOETTINGEN |
|
| R071 | Expiry of right |
Ref document number: 611306 Country of ref document: EP |